Anti-TRP1 Mouse Monoclonal Antibody (Clone TA99)

SK 413

Antigen:                                Human TRP1 (TYRP1, PAA, gp75)
Clone Name:                        TA99
Isotype:                                  Mouse IgG2a
Application(s):                   Immunocytochemistry, Immunohistochemistry, Immunoprecipitation, Western Blot
Reactivity*:                          Mouse, Human
* As reported in the literature and other commercial supplier websites


Clone TA99 is a mouse monoclonal antibody that reacts with tyrosinase-related protein 1 (TRP1), a 75kDa differentiation-related human glycoprotein (gp75), formerly referred to as pigmentation-associated antigen (PAA).  It is expressed by pigmented melanoma cells and cultured melanocytes. TRP1 is involved in the pigmentation machinery of melanocytes and can be used as a differentiation marker.


This antibody was derived in 1985 by injection of whole human melanoma cells (SK-MEL-23) into mice. Splenocytes from these immunized mice were fused with NS-1 cells to generate hybridomas producing anti-TRP1 antibodies.


  • Francisco X. Real, MD, PhD, formerly at Memorial Sloan Kettering
  • Lloyd J. Old, MD, former William E. Snee Chair in Cancer Immunology, Memorial Sloan Kettering; former Director, New York Branch, Ludwig Institute for Cancer Research
  • Timothy M. Thomson, MD, PhD

Key References

  • Thomson TM et al. (1985) Pigmentation-Associated Glycoprotein of Human Melanomas and Melanocytes: Definition with a Mouse Monoclonal Antibody. Journal of Investigative Dermatology 85: 169-174 (PubMed ID: 3926906)
  • Bevaart L et al. (2006) The high-affinity IgG receptor, FcgammaRI, plays a central role in antibody therapy of experimental melanoma. Cancer Research 66: 1261-1264 (Pubmed ID: 16452176)

Licensing Information

This hybridoma may be licensed nonexclusively for commercial purposes. For more information, please contact

Additional Information

Purified antibody may be available for sale through the Memorial Sloan Kettering Antibody & Bioresource Core Facility.  Please email for further information.

Stage of Development

Ready to use